336 related articles for article (PubMed ID: 24610703)
21. [Alpha emitter radium-223 dichloride: new therapy in castration-resistant prostate cancer with symptomatic bone metastases].
Heinzer H; König F; Klutmann S
Urologe A; 2014 Apr; 53(4):519-23. PubMed ID: 24604017
[TBL] [Abstract][Full Text] [Related]
22. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
[TBL] [Abstract][Full Text] [Related]
23. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
[TBL] [Abstract][Full Text] [Related]
24. Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel.
Baldari S; Boni G; Bortolus R; Caffo O; Conti G; De Vincentis G; Monari F; Procopio G; Santini D; Seregni E; Valdagni R
Crit Rev Oncol Hematol; 2017 May; 113():43-51. PubMed ID: 28427521
[TBL] [Abstract][Full Text] [Related]
25. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
Tauber R; Gschwend J; Scheidhauer K; Eiber M; Krönke M
Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.
Sartor O; Hoskin P; Coleman RE; Nilsson S; Vogelzang NJ; Petrenciuc O; Staudacher K; Thuresson M; Parker C
Prostate; 2016 Jul; 76(10):905-16. PubMed ID: 27004570
[TBL] [Abstract][Full Text] [Related]
27. [Radium 223 in castration resistant prostate cancer.].
Loizaga-Iriarte A; Camargo Ibargarai I; Senarriaga-Ruiz de la Illa N; Lacasa-Viscasillas I; Unda-Urzaiz M
Arch Esp Urol; 2018 Sep; 71(8):696-703. PubMed ID: 30319129
[TBL] [Abstract][Full Text] [Related]
28. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
[TBL] [Abstract][Full Text] [Related]
29. Radium-223 dichloride: a new paradigm in the treatment of prostate cancer.
Anido Herranz U; Fernández Calvo O; Afonso Afonso FJ; Rodríguez Martínez de Llano S; Lázaro Quintela M; León Mateos L; Vázquez Estévez S; Antón Aparicio LM
Expert Rev Anticancer Ther; 2015 Mar; 15(3):339-48. PubMed ID: 25555355
[TBL] [Abstract][Full Text] [Related]
30. Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial.
Vogelzang NJ; Coleman RE; Michalski JM; Nilsson S; O'Sullivan JM; Parker C; Widmark A; Thuresson M; Xu L; Germino J; Sartor O
Clin Genitourin Cancer; 2017 Feb; 15(1):42-52.e8. PubMed ID: 27613490
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Matsubara N; Kinuya S; Hosono M; Yajima Y; Doi T
Int J Clin Oncol; 2017 Oct; 22(5):954-963. PubMed ID: 28478485
[TBL] [Abstract][Full Text] [Related]
32. [Radium-223 dichloride in patients with castration-refractory prostate cancer].
Winter BM; von Rundstedt FC; Grimm MO
Urologe A; 2017 Nov; 56(11):1435-1439. PubMed ID: 29022046
[TBL] [Abstract][Full Text] [Related]
33. Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer.
Borsò E; Boni G; Galli L; Ricci S; Farnesi A; Mazzarri S; Cianci C; Mariani G; Falcone A
Future Oncol; 2015; 11(2):323-31. PubMed ID: 25075962
[TBL] [Abstract][Full Text] [Related]
34. The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.
De Luca R; Costa RP; Tripoli V; Murabito A; Cicero G
Oncology; 2018; 94(3):161-166. PubMed ID: 29241166
[TBL] [Abstract][Full Text] [Related]
35. Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer.
Nilsson S
Curr Oncol Rep; 2016 Feb; 18(2):14. PubMed ID: 26779616
[TBL] [Abstract][Full Text] [Related]
36. Metabolism and pharmacokinetics of radium-223 in prostate cancer.
Yeku O; Slovin SF
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):843-9. PubMed ID: 25740232
[TBL] [Abstract][Full Text] [Related]
37. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
Li J; Armstrong AJ
Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
[No Abstract] [Full Text] [Related]
38. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
Gallicchio R; Mastrangelo PA; Nardelli A; Mainenti PP; Colasurdo AP; Landriscina M; Guglielmi G; Storto G
Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
[TBL] [Abstract][Full Text] [Related]
39. Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer: Risk Factors and Practical Considerations.
Jacene H; Gomella L; Yu EY; Rohren EM
Clin Genitourin Cancer; 2018 Aug; 16(4):e919-e926. PubMed ID: 29678471
[TBL] [Abstract][Full Text] [Related]
40. [Radium-223 treatment of bone metastases from castration-resistant prostate cancer].
Mortensen J; Højgaard L
Ugeskr Laeger; 2014 Jul; 176(30):1399-402. PubMed ID: 25292232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
